Fetal Anomaly Screening and Common Fetal Defects by Dr C. Verenga

Value of the Information & Strength of the Argument

The presentation provides valuable insights into the practical implementation of fetal anomaly screening in a low-resource setting, supported by local data and reference to international literature. The argumentation is coherent, advocating for a staged screening strategy and comprehensive genetic testing. However, the evidence is largely based on expert opinion and local experience rather than systematic review, and some claims lack specific citations.

Scientific Rigor, Source Quality, Title Accuracy

The speaker references the work of Argyro Syngelaki and WHO data, but does not provide specific citations or URLs. The title accurately reflects the content. The presentation is scientifically grounded but would benefit from more rigorous referencing. No comments were provided for analysis.

The title accurately reflects the content, which covers screening strategies and common fetal defects.

7/10

Presentation by a fetal medicine specialist with reference to local data and established literature (e.g., Syngelaki), but lacks detailed citations and peer-reviewed sources.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction and overview of the presentation roadmap.
• 05:00Discussion on why fetal defects matter, citing WHO data and local statistics.
• 10:00Presentation of local data from 9,513 pregnancies showing defect rates and distribution.
• 15:00Explanation of the trimester-based screening approach, referencing Syngelaki's work.
• 20:00Discussion on the importance of third-trimester scans for late-evolving defects.
• 25:00Overview of genetic testing options including NIPT, karyotype, microarray, and whole exome sequencing.
• 30:00Categorization of defects into lethal, major, and minor, and the management pathway including MDT and counseling.

• WHO data on congenital anomalies — Referenced in the presentation to highlight the burden of congenital anomalies in under-five mortality.
• Argyro Syngelaki's research on first-trimester screening — Referenced to support detection rates of fetal defects in the first trimester.

• ISUOG guidelines on fetal ultrasound — International guidelines supporting the use of ultrasound in fetal anomaly screening.